Bombay Hospital Journal ContentsHomeArchivesSearchBooksFeedback



Home > Table of Contents > Cost Effectiveness/Yield/Medical Economics
 
Cough Syrups - Do They have any Role to Play in Modern Times?
OP Kapoor
 

In the past, I have stressed that cough syrups have no more a role to play in patients having clinical symptoms of cough or dyspnoea, all of whom should be treated with inhalers rather than cough syrups.

Over the years, I have noticed that many patients having cough due to upper respiratory virus infection and associated viral cold, ask for a cough syrup to suppress the cough, which is acceptable.

There is another group of patients, who have mild viral bronchitis, which is not allergic in nature because it gradually subsides and disappears within a week. Since these patients have a very short and acute illness, they get shaken up if they are prescribed inhalers for their chest symptoms as in the mind of the public these inhalers are normally prescribed for ‘chronic asthma’. Such patients can be given expectorant cough syrups, which will liquefy the sputum and bring it out rather than suppressing it, though steam inhalations can do the same job. Often these patients themselves ask for cough syrups.

Finally, patients with an incurable disease of the lungs and pleura like malignancy or lymphoma, very bad MDR Tuberculosis or very progressive interstitial lung disease (ILD) need suppressive cough syrups containing codeine so that they can live a comfortable life.

 

CLARITHROMYCIN IN STABLE CORONARY HEART DISEASE MAY INCREASE MORTALITY
Short term treatment with the macrolide antibiotic clarithromycin in patients with stable coronary heart disease may raise the risk of dying of cardiovascular causes. In a randomised controlled multicentre trial by Jespersen and colleagues, more than 4300 patients with myocardial infarction or angina pectoris received either clarithromycin 500 mg/day or placebo for two weeks. All cause mortality was higher in the clarithromycin arm (hazard ratio 1.27, 95% CI 1.03 to 1.54), and patients in this group were significantly more likely to have died from cardiovascular causes (1.45, 1.09 to 1.92).

BMJ, 2006; 22.

 
Ex. Hon. Physician, Jaslok Hospital and Bombay Hospital, Mumbai, Ex. Hon. Prof. of Medicine, Grant Medical College and JJ Hospital, Mumbai 400 008.
Top